Particle size reduction is increasingly utilized to address a range of formulation issues facing oral solid and inhaled dosage forms. Stability, flowability, dissolution rate and bioavailability are critical performance parameters impacted by particle size distribution. Micronization through jet milling is a core strength of Lonza with unparalleled expertise, track record and capacity in place to meet these challenges.
Micronization is an established technology and manufacturing technique for producing APIs within a 1–10 micron average particle size. We utilize proprietary jet milling technology to effectively meet specific particle size distribution targets across the full range of compound properties. Phase-appropriate jet mills are in place for non-GMP development studies and cGMP production of clinical and commercial intermediates. Specialized processing is in place for handling highly potent compounds and APIs with elastic or semi-solid properties.
Our particle size reduction services have a range of applications for oral, inhaled and transdermal drug delivery:
- Improve API dissolution rate to provide sufficient bioavailability
- Improve palatability properties of drug compounds
- Generate API particles within a tight particle size distribution for proper delivery to the lungs
- Help ensure absorption of a drug for transdermal delivery